EP3752133 - SUSTAINED RELEASE FORMULATIONS OF BEMPEDOIC ACID [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 20.05.2022 Database last updated on 22.08.2024 | |
Former | Examination is in progress Status updated on 09.07.2021 | ||
Former | Request for examination was made Status updated on 20.11.2020 | ||
Former | The international publication has been made Status updated on 24.08.2019 | ||
Former | unknown Status updated on 18.03.2019 | Most recent event Tooltip | 20.05.2022 | Application deemed to be withdrawn | published on 22.06.2022 [2022/25] | Applicant(s) | For all designated states Esperion Therapeutics, Inc. 3891 Ranchero Drive Suite 150 Ann Arbor, MI 48108 / US | [2020/52] | Inventor(s) | 01 /
LALWANI, Narendra, Dhanraj 8354 Pier Point Ct. South Lyon, MI 48178 / US | 02 /
ABDELNASSER, Mohamed 7 Topaz Ct. New York, NY 10956 / US | 03 /
PINKOSKY, Stephen, Lawrence 881 Simpson Street Plymouth, MI 48170 / US | 04 /
CRAMER, Clay, Thomas 7765 Fischers Way Dexter, MI 48130 / US | [2020/52] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [N/P] |
Former [2020/52] | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | Application number, filing date | 19709204.2 | 15.02.2019 | [2020/52] | WO2019US18356 | Priority number, date | US201862710417P | 16.02.2018 Original published format: US 201862710417 P | US201862774083P | 30.11.2018 Original published format: US 201862774083 P | [2020/52] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019161307 | Date: | 22.08.2019 | Language: | EN | [2019/34] | Type: | A1 Application with search report | No.: | EP3752133 | Date: | 23.12.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 22.08.2019 takes the place of the publication of the European patent application. | [2020/52] | Search report(s) | International search report - published on: | EP | 22.08.2019 | Classification | IPC: | A61K9/20, A61K9/16, A61K31/20 | [2020/52] | CPC: |
A61K9/2054 (EP,IL,KR);
A61K31/20 (EP,IL,KR);
A61K47/20 (KR);
A61K47/38 (KR);
A61K9/1617 (EP,IL,KR);
A61K9/1652 (EP,IL,KR);
A61K9/2013 (KR);
A61K9/2018 (EP,IL);
A61K9/2059 (EP,IL,KR);
A61K9/4825 (KR);
A61K9/4858 (KR);
A61K9/4866 (KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/52] | Title | German: | RETARD-FORMULIERUNGEN VON BEMPEDOINSÄURE | [2020/52] | English: | SUSTAINED RELEASE FORMULATIONS OF BEMPEDOIC ACID | [2020/52] | French: | FORMULATIONS À LIBÉRATION PROLONGÉE D'ACIDE BEMPEDOIQUE | [2020/52] | Entry into regional phase | 10.09.2020 | National basic fee paid | 10.09.2020 | Designation fee(s) paid | 10.09.2020 | Examination fee paid | Examination procedure | 10.09.2020 | Examination requested [2020/52] | 10.09.2020 | Date on which the examining division has become responsible | 31.03.2021 | Amendment by applicant (claims and/or description) | 13.07.2021 | Despatch of a communication from the examining division (Time limit: M06) | 25.01.2022 | Application deemed to be withdrawn, date of legal effect [2022/25] | 15.02.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2022/25] | Fees paid | Renewal fee | 25.02.2021 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 28.02.2022 | 04   M06   Not yet paid |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [I]WO2017023165 (DEZIMA PHARMA B V [NL]) [I] 1-47 * page 6, line 10 - line 18 * * page 7, line 24 - line 26 * * page 11, line 13 - line 26 ** claim - *; | [L]WO2018218147 (ESPERION THERAPEUTICS INC [US]) [L] 1-3,5-9,11-13,20-28,31-47 * page 54; table 32 * * page 54; table 34 * | by applicant | US3845770 | US3865108 | US3916899 | US3995631 | US4002173 | US4008719 | US4088864 | US4111202 | US4160020 | US4207893 | US4327725 | US4519801 | US4578075 | US4681583 | US5019397 | US5156850 | US2005043278 | US7335799 | US8163798 | US8629179 | - CONOVER, W., J. Chem. Educ., (19980000), vol. 75, no. 2, page 153 | - VIJAY KUMAR THAKUR; MANJU KUMARI THAKUR, Handbook of Polymers for Pharmaceutical Technologies: Biodegradable Polymers, Wiley, (20150000), vol. 3 | - Remington, The Science and Practice of Pharmacy, Mack Pub. Co. | - REMINGTON, J. P., Remington, The Science and Practice of Pharmacy, Mack Pub. Co., (19950000), pages 679 - 687 | - Handbook of Pharmaceutical Excipients, American Pharmaceutical Association | - Pharmaceutical Dosage Forms: Tablets, Marcel Dekker, Inc. | - Remington's Pharmaceutical Sciences | - GI TRACT; SANTUS; BAKER, "Osmotic drug delivery: a review of the patent literature", Journal of Controlled Release, (19950000), vol. 35, pages 1 - 21 | - SCOTT; ROFF, Handbook of Common Polymers, Chemical Rubber Co. | - ASRIH, M.; F. R. JORNAYVAZ, Molecular and Cellular Endocrinology., (20150000), vol. 418, pages 55 - 65 | - MACHADO, M. V.; H. CORTEZ-PINTO, Journal of Hepatology, (20130000), vol. 58, pages 1007 - 1019 | - PACANA, T.; A. J. SANYAL., FlOOOPrime Rep., (20150000), vol. 7, page 28 | - YEH, M. M.; E. M. BRUNT., Gastroenterology, (20140000), vol. 147, pages 754 - 764 | - BILEN et al., Curr Atheroscler Rep., (20160000), vol. 18, no. 10, page 61 | - "USP35 NF30, 2012: U. S. Pharmacopoeia National Formulary, The United States pharmacopeia", United States Pharmacopeial Convention, (20110000), pages 5642 - 5648 |